Patent details

EP2877177 Title: DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN

Basic Information

Publication number:
EP2877177
PCT Application Number:
PCT/EP/2013/065907
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP137458139
PCT Publication Number:
WO/2014/016433
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN
French Title of Invention:
DÉRIVÉS DE TYPE AZAINDAZOLE OU DIAZAINDAZOLE POUR LE TRAITEMENT DE LA DOULEUR
German Title of Invention:
AZAINDAZOL- ODER DIAZAINDAZOL-DERIVATE ZUR BEHANDLUNG VON SCHMERZEN
SPC Number:

Dates

Filing date:
29/07/2013
Grant date:
26/10/2016
EP Publication Date:
26/10/2016
PCT Publication Date:
30/01/2014
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
03/06/2015
EP B1 Publication Date:
26/10/2016
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
29/07/2033
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
29/07/2013
 
 

Name:
Pierre Fabre Médicament
Address:
45, Place Abel Gance, 92100 Boulogne-Billancourt, France (FR)

Agent

Name:
REGIMBEAU
From:
17/01/2017
Address:
RUE DE CHAZELLES 20, 75847, PARIS CEDEX 17, France (FR)
To:

Inventor

1

Name:
SOKOLOFF Pierre
Address:
France (FR)

2

Name:
CACHOUX Frédéric
Address:
France (FR)

Priority

Priority Number:
12305922
Priority Date:
27/07/2012
Priority Country:
European Patent Office (EPO) (EP)

Classification

Main IPC Class:
A61K 31/437;

Annual Fees

Annual Fee Due Date:
31/07/2025
Annual Fee Number:
13
Annual Fee Amount:
180 Euro
Expected Payer:
Last Annual Fee Payment Date:
25/06/2024
Last Annual Fee Paid Number:
12
Last Annual Fee Paid Amount:
165 Euro
Payer:
ACUMASS SARL
Filing date Document type Number of pages
17/01/2017 Incoming Correspondence (Post) 2